论文部分内容阅读
目的:探讨重组干扰素α_1b、α_2b 抗病毒的近、远期疗效及对临床预后的影响。方法:重组干扰素α_1b 治疗组37例,重组干扰素α_2b 治疗组71例及对照组32例,治疗后随访1～7年。结果:治疗结束时,治后6月、1～7年 HBeAg、HBV-DNA 转阴率α_1b 组分别为48.65%、54.54%、68.96%、71.42%、71.42%、78.94%、72.22%、75.00%、66.67%,α_2b 组分别为53.50%、58.49%、61.53%、61.76%、70.83%、69.56%、62.50%,均显著高于对照组(P 值<0.05或 P 值<0.01)。慢性肝炎中度,治疗前 ALT 超过100U/L,HBeAg P/N 比值小于5者疗效较好。治疗组病情稳定比率为49.38%,高于对照组(P 值<0.05),且病情稳定比率以 HBeAg、HBV-DNA 转阴者为高(P 值<0.05)。结论:重组干扰素α_1b 与α_2b 均为有效的抗乙肝病毒药物,且远期疗效优于近期疗效,干扰素治疗后 HBeAg、HBV-DNA 转阴与改善临床预后似有一定关系。
Objective: To investigate the short-term and long-term effects of recombinant interferon alpha 1 b and alpha 2 b antiviral drugs on clinical prognosis. Methods: Thirty-seven patients were treated with recombinant interferon alb, 71 patients were treated with interferon alfa-2b and 32 patients were treated with interferon alfa-2b. The patients were followed up for 1 to 7 years. Results: At the end of treatment, the HBeAg and HBV-DNA negative rates of α_1b group were 48.65%, 54.54%, 68.96%, 71.42%, 71.42%, 78.94%, 72.22%, 75.00% , 66.67% andα_2b group were 53.50%, 58.49%, 61.53%, 61.76%, 70.83%, 69.56% and 62.50% respectively, which were significantly higher than those in the control group (P <0.05 or P <0.01). Chronic hepatitis moderate, pre-treatment ALT over 100U / L, HBeAg P / N ratio of less than 5 were better. The stable disease rate in treatment group was 49.38%, higher than that in control group (P <0.05), and stable disease rate was higher in HBeAg and HBV-DNA negative patients (P <0.05). Conclusion: Both recombinant IFNα_1b and α_2b are effective anti-HBV drugs, and the long-term curative effect is better than the short-term efficacy. The relapse of HBeAg and HBV-DNA after interferon treatment may be related to the improvement of clinical prognosis.